Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909900 | 0.85 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL20890512 | 0.85 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL536688 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL30382126 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL830319 | 0.83 | KCNH2 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL20910195 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL22251076 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL130926 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL536812 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL536703 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210381-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | HCRTR1 309/4885HCRTR2 329/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HCRTR1 4613/4885HCRTR2 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.